Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
about
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?Application and interpretation of current autophagy inhibitors and activators.Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects.Autophagy function and its relationship to pathology, clinical applications, drug metabolism and toxicity.
P2860
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
@en
type
label
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
@en
prefLabel
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
@en
P2860
P356
P1476
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
@en
P2093
S Galimberti
P2860
P304
P356
10.2147/CMAR.S7960
P407
P577
2010-06-28T00:00:00Z